argenx jumps as investors eye May 10 FDA decision for VYVGART seronegative gMG
argenx shares rose as traders positioned ahead of the FDA’s May 10, 2026 action date for VYVGART in AChR antibody–seronegative generalized myasthenia gravis. The priority-review decision is a near-term binary catalyst for label expansion of its flagship FcRn therapy.
1) What’s moving the stock
argenx SE’s American depositary shares (ARGX) traded higher Monday as investors focused on an imminent regulatory catalyst: the FDA’s target action date of May 10, 2026 for a priority-review supplemental BLA seeking to expand VYVGART (efgartigimod) into acetylcholine receptor antibody–seronegative generalized myasthenia gravis (gMG). (argenx.com)
2) Why it matters
A favorable decision would broaden the addressable gMG population for argenx’s flagship FcRn franchise and could reinforce confidence in continued demand for VYVGART and VYVGART Hytrulo, which have been the company’s key growth drivers. With the date so close, the move looks consistent with pre-decision positioning rather than a single new company announcement. (argenx.com)
3) What to watch next
The main swing factor is the FDA outcome on May 10: approval would set up near-term prescribing expansion, while a complete response letter or a delay would likely pressure the shares given expectations embedded into the stock ahead of the event. Investors are also watching for the company’s next earnings update (currently expected May 7, 2026) for any fresh commentary on launch momentum, pipeline timelines, and regulatory readiness going into the decision. (tipranks.com)